Pitavastatin Magnesium has 8 known drug interactions based on U.S. FDA drug labeling data. Of these, 1 are contraindicated combinations that should be avoided entirely. 3 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Cyclosporine, Erythromycin, Gemfibrozil. Patients taking Pitavastatin Magnesium should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 8
- Contraindicated
- 1
- Major
- 3
- Moderate
- 3
Contraindicated (1)
- Pitavastatin Magnesium + Cyclosporine— Cyclosporine significantly increases pitavastatin exposure and increases the risk of myopathy and rhabdomyolysis. Concom…
Major (3)
- Pitavastatin Magnesium + Erythromycin— Erythromycin significantly increases pitavastatin exposure and increases the risk of myopathy and rhabdomyolysis. Dosage…
- Pitavastatin Magnesium + Gemfibrozil— Gemfibrozil may cause myopathy when given alone. Risk of myopathy and rhabdomyolysis is increased with concomitant use w…
- Pitavastatin Magnesium + Rifampin— Rifampin significantly increases peak pitavastatin exposure and increases the risk of myopathy and rhabdomyolysis. Dosag…
Moderate (3)
- Pitavastatin Magnesium + Colchicine— Cases of myopathy and rhabdomyolysis have been reported with concomitant use of colchicine with pitavastatin. Risk/benef…
- Pitavastatin Magnesium + Fibrates— Fibrates may cause myopathy when given alone. Risk of myopathy and rhabdomyolysis is increased with concomitant use with…
- Pitavastatin Magnesium + Niacin— Risk of myopathy and rhabdomyolysis may be increased with concomitant use of lipid-modifying doses (≥1 g/day) of niacin …